Membership of cirrhosis guideline Committee

Transcription

1 Membership of cirrhosis guideline Committee The Committee will operate as an advisory Committee to NICE s Board, developing a guideline on cirrhosis. The terms of reference and standing orders for the Committee can be found in appendix D of Developing NICE guidelines: the manual. Membership list Name Chair Phillip Harrison Core members / Members Iain Brew Andrew Fowell Lynda Greenslade Mark Hudson Andrew Langford Susan McRae Marsha Morgan Gerri Mortimore Valerie Ross Topic expert members David Fitzmaurice John O Grady Phillip Johnson Job Title, Organisation Consultant Hepatologist, King s College Hospital General Practitioner, Leeds Community Healthcare NHS Trust Consultant Hepatologist, Portsmouth Hospitals NHS Trust Clinical Nurse Specialist in Hepatology, Royal Free London Foundation Trust Consultant Hepatologist, Newcastle Hospitals NHS Trust Patient/Carer Member Patient/Carer Member Principal Research Associate and Honorary Consultant Physician, UCL Institute for Liver and Digestive Health, University College London Medical School Lead CNS Liver, Derby Hospitals NHS Foundation Trust Lead Pharmacist Hepatology, Barts Health NHS Trust Professor of Primary Care, University of Birmingham Professor of Hepatology, King's College Hospital Professor of Oncology, University of Liverpool & Clatterbridge Cancer Centre

2 Rachel Pryke Roy Sherwood General Practitioner Partner, Winyates Health Centre, Redditch Professor of Clinical Biochemistry, King's College London Date last reviewed: 06/07/2016

3 Declaration of Interests Name Job title, organisation Declarations of Interest, date declared Type of interest Decision taken Iain Brew General Practitioner, Leeds Community Healthcare NHS Trust At recruitment: GP with special interest in hepatitis C. non At recruitment: Contributor to the APPHG Report on Liver Disease At recruitment: Has received honoraria, travel and expenses from Janssen for attending, speaking at and chairing meetings about treatment of hepatitis C. At recruitment: Has received honoraria, travel and expenses from AbbVie for attending, speaking at and chairing meetings about treatment of hepatitis C. At recruitment: I have received payments ( 200 x 2) for articles on liver health published in the British Journal of Primary Care Nursing. 11/07/2014: non 04/09/2014:

4 Payment for attending and chairing advisory boards for Janssen and AbbVie. 17/10/2014: Janssen paid for attendance at BASL in Newcastle (October 2014) 26/11/2014: No new 21/01/2015: No new 18/02/2015: Delivered a lecture on hepatitis C treatment in prisons for Gilead: honorarium payable. 18/02/2015: Conference and travel costs covered by Janssen for a hepatitis C meeting. 26/03/2015: No new 30/04/2015: No new 25/06/2015: AbbVie paying honorarium and travel costs 10 July meeting about hepatitis C treatments. 29/07/2015: 02/09/2015: No new 14/03/2016: No new David Fitzmaurice Professor of Primary Care, University of Birmingham 15/01/2015: None 21/01/2016: No new Andrew Fowell Consultant Hepatologist, Portsmouth Recruitment: none declared.

5 Hospitals NHS Trust 11/07/2014: No new 04/09/2014: Received travel expenses from Janssen to attend a conference. Secretary of the Wessex Gut Club (Gastroenterological society). Has responsibility for organising twice yearly meetings. All money paid is directly to the Gut Club. Meetings took place on the following dates and pharma company funding is outlined: November 2013: Roche, Janssen, AbbVie, Gilead, Ferring, Falk, Novartis, Vifor, Pentax July 2014: Janssen, Gilead, Falk, Tillots, Vifor, Ferring November 2014: dealt with organising programme of speakers only. Nonpersonal Roche: Nonpersonal 17/10/2014: No new 26/11/2014: No new 21/01/2015: No new 18/02/2015: No new

6 26/03/2015: Received travel and from Janssen to attend a conference in /04/2015: No new 25/06/2015: No new 29/07/2015: Organised speakers for the Wessex Gut Club meeting in July non 02/09/2015: Organising speakers for the Wessex Gut Club meeting taking place in November non 14/03/2016: Accepted sponsorship from Gilead to attend the EASL International Liver Conference, April 2016: economy class travel, hotel and meeting registration fee. Lynda Greenslade Clinical Nurse Specialist in Hepatology, Royal Free London Foundation Trust 11/07/2014: Norgine Advisory Board Member: 2/3 December 2013: and subsistence 8 April 2014: and subsistence Advisory Board calls: 22 and 29 June /07/2014: Norgine Educational

7 Meeting Committee Member: telephone call 14 and 26 November 2013, 16 December 2013, 7 and 12 May One-off payment for being part of the education committee and a talk. 11/07/2014: Norgine-sponsored liver nurses meeting 6 and 7 June 2014: and subsistence. Payment received for chairing one session and giving one talk. 11/07/2014: Payment received from speaking at the (Norginesponsored) Royal College of Nursing congress on 18 June /07/2014: Data on hepatic patients from Royal Free Foundation Trust given to advisory board meeting for real world data, for Norgine. 11/07/2014: Sponsored by Norgine to go to the European Association for the Study of the Liver conference. 04/09/2014: Janssen paid for standard travel expenses to attend BASL Liver meeting. non

8 17/10/2014: No new 26/11/2014: Attended Norginesponsored Liver Nurses Educational Meeting on 21 and 22 November On the education board, chaired some sessions and gave a talk; and subsistence provided. 21/01/2015: No new 18/02/2015: No new 26/03/2015: Funding for travel and received from Janssen to attend the European Association for the Study of the Liver conference /04/2015: No new 25/06/2015: Attended Norginesponsored liver nurses meeting 15 and 16 May 2015: and subsistence. Payment for chairing one session and giving one talk. 29/07/2015: No new 02/09/2015: No new 14/03/2016: No new Phillip Harrison Consultant Hepatologist, King s 07/01/2014: None declared.

9 Mark Hudson College Hospital Consultant Hepatologist, Newcastle Hospitals NHS Trust 11/07/2014: 04/09/2014: 17/10/2014: 26/11/2014: 21/01/2015: 18/02/2015: 26/03/2015: 30/04/2015: 25/06/2015: 29/07/2015: 02/09/2015: 14/03/2016: At recruitment: Has advised Astellas on immunosuppression within the last year. At recruitment: Has advised Novartis on immunosuppression within the last year. At recruitment: Has advised Norgine on rifaximin within the last year. At recruitment: I am the Co-Chief Investigator on the impact of rifaximin-α on the NHS Hospital Resource use associated with the management of patients with Hepatic Encephalopathy: A retrospective observational study (IMPRESS). non The IMPRESS study is a multicentre CLRN Portfolio study funded by Norgine. The trial has been in development since April 2014.

10 Has received no payment or personal gain from the IMPRESS study. 11/07/2014: No new 04/09/2014: No new 17/10/2014: Attended a Norgine advisory board on rifaximin. Received a payment on 27 October 2014 for attending a Norgine advisory board to discuss the natural history of hepatic. 26/11/2014: No new 21/01/2015: No new 18/02/2015: No new 26/03/2015: No new 30/04/2015: No new 25/06/2015: Speaker for Norgine at a meeting (2 June) on hepatic. Chaired a session for Abbvie on 23 June viral hepatitis. 29/07/2015: Novartis provided travel support to attend the International Liver Transplant Society meeting in Chicago from 7 to 11 July /09/2015: No new

11 14/03/2016: Phillip Johnson Professor of Oncology, University of Liverpool & Clatterbridge Cancer Centre At recruitment: Oneoff advisory board meetings: Astellas (13 February 2014) Boehringer- Ingelheim (17 October 2014). (as a co-optee) At recruitment: funding received from Bayer Healthcare for 1- year support of research nurse/data manager from September 2014 to August Nonpersonal (as a co-optee) 26/03/2015: Travel expenses from Wako Life Sciences to attend an American Association for the Study of Liver Diseases meeting. (as a co-optee) Andrew Langford Patient/Carer Member At recruitment: In the last year, the British Liver Trust have received: funding from Roche for the development of case studies on "Confronting the silent epidemic: a critical review of hepatitis C management in the UK" a Hepatitis Awareness Leading Outcomes report (29 April 2013) funding from Astellas as support from (15 Nonpersonal

12 May 2013) funding from Janssen for RCGP accreditation (2 August 2014) funding from Lundbeck for PR support funding from AbbVie as honoraria (panel) funding from Galderma as honoraria (NMSC) funding from Janssen as honoraria (EASL) 11/07/2014: 04/09/2014: British Liver Trust press release regarding rifaximin for hepatic. 17/10/2014: No new 26/11/2014: 21/01/2015: No new 18/02/2015: 26/03/2015: No new 30/04/2015: The British Liver Trust was gifted a Fibroscan machine by Norgine. 25/06/2015: No new 29/07/2015: No new 02/09/2015: No new 14/03/2016: No new Nonpersonal non Nonpersonal Susan Patient/Carer At recruitment:

13 McRae Member Employed by the Hepatitis C Trust, the UK HCV patient charity. 11/07/2014: No new 04/09/2014: No new 17/10/2014: No new 26/11/2014: No new 21/01/2015: No new 18/02/2015: No new 26/03/2015: No new 30/04/2015: No new 25/06/2015: No new 29/07/2015: Expenses paid for judging quality in care hepatitis C 2015 entries, organised by PMGroup with funding from Bristol- Myers Squibb and Gilead. 02/09/2015: No new 14/03/2016: Marsha Morgan Principal Research Associate and Honorary Consultant Physician, UCL Institute for Liver and Digestive Health, University College London At recruitment: Has taken part in symposia both in the UK and abroad on aspects of alcohol dependence, alcohol-related liver disease, nutrition in chronic liver disease and hepatic. non

14 Medical School At recruitment: A member of the Advisory board of the Institute of Alcohol Studies. Receive an annual stipend used to support research activities. 11/07/2014: No new 04/09/2014: No new 17/10/2014: Author of Cochrane review currently in development on hepatic. non 26/11/2014: No new 21/01/2015: No new 18/02/2015: No new 26/03/2015: No new 30/04/2015: No new 25/06/2015: No new 29/07/2015: 02/09/2015: No new 14/03/2016: No new Gerri Mortimore Lead CNS Liver, Derby Hospitals NHS Foundation Trust 11/07/2014: None declared 04/09/2014: 17/10/2014: No new 26/11/2014: 21/01/2015: No new

15 18/02/2015: No new 26/03/2015: No new 30/04/2015: No new 25/06/2015: No new 29/07/2015: No new 02/09/2015: 14/03/2016: John O Grady Rachel Pryke Valerie Ross Professor of Hepatology, King's College Hospital General Practitioner Partner, Winyates Health Centre, Redditch Lead Pharmacist Hepatology, Barts Health NHS Trust At recruitment: None declared. 30/04/2015: No new At recruitment: Speaker fee for attending RCGP Conference 2 October 2014 in order to man a stand on bariatric surgery in conjunction with RCGP Nutrition Group and BOMSS, funded by Ethicon. The stand focuses on bariatric surgery care and postsurgical follow up. 21/01/2015: No new At recruitment: Has contributed to advisory boards for Janssen the marketing of drugs for hepatitis C within the last 12 months. At recruitment: Has contributed to advisory boards for Gilead the marketing of (as a co-optee)

16 drugs for hepatitis C within the last 12 months. Payment received including travel expenses. At recruitment: Gave a presentation at a Bristol-Myers Squibb training day on 14 July Presented on background to the role and responsibilities of the pharmacist in the treatment of HCV and the managed entry of new therapies in this area. At recruitment: Attended British Association for the Study of the Liver meeting in Newcastle on 15 to 17 September Janssen funded reduced conference attendance fee, travel, and subsistence. 11/07/2014: No new 04/09/2014: No new 17/10/2014: 26/11/2014: No new 21/01/2015: No new 18/02/2015: No new 26/03/2015: Funding for travel and

17 received from Abbvie to attend European Association for the Study of the Liver conference in April /03/2015: Attended an advisory board for AbbVie. 30/04/2015: No new 25/06/2015: No new 29/07/2015: Was a QiC Hepatitis Projects Judging panel member, sponsored by Gilead and Bristol- Myers Squibb on 14 July /07/2015: Was a presenter/facilitator at a Bristol-Myers Squibb sponsored nurse training day on 31 July /09/2015: No new 14/03/2016: Roy Sherwood Professor of Clinical Biochemistry, King's College London At recruitment: None declared. 21/01/2015: Receives a salary from the Pathology Department at King s College London which, as of 1 January 2015, is a private company (Viapath). (as a co-optee)

18 Date last reviewed: 06/07/2016